ImageneBio, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
In April 2026, ImageneBio closed a $30 million private placement with new and existing investors. As of June 30, 2026, the company holds $136.2 million in cash and marketable securities, providing runway into Q1 2028. Q2 2026 net loss was $10.2 million ($0.63 per share) on R&D expenses of $6.7 million and G&A expenses of $5.1 million. The company appointed Yanina Grant-Huerta as CFO and Matt Robbins as General Counsel, and continues Phase 2b ADAPTIVE trial progression with topline data expected Q4 2027; Phase 2 alopecia areata trial planned for 2026.
Why this rating
Financing extends runway 18+ months and covers 3.3x current quarterly burn; leadership appointments strengthen execution. Material for a $41.7M market-cap biotech but routine quarterly progress.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.